Program
Pan-RAS Molecular Glue ERAS-0015
Also written as “ERAS-0015”, “ERAS-0015 in combination” and “JYP0015”.
Its studies are mostly in Neoplasm Metastasis · Lung Neoplasms · Carcinoma, Non-Small-Cell Lung, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Erasca | 11 open or running | phase 1since May 14, 2025 | May 14, 2025 | May 1, 2028phase 1 · NCT06983743 |
| Guangzhou JOYO Pharma | 11 open or running | phase 2since Mar 19, 2025 | Mar 19, 2025 | none ahead |
| Tango Therapeutics | 11 open or running | phase 2since Oct 20, 2026 | Oct 20, 2026 | Nov 2031phase 2 · NCT07897734 |
Also a collaborator on its studies: Merck.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 19, 2025First study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Guangzhou JOYO PharmaGuangzhou JOYO Pharma · NCT06895031 · 210 planned · China
- May 14, 2025Erasca’s first study: phase 1 study in Neoplasm MetastasisNew to ErascaErasca · NCT06983743 · 600 planned · United States, Canada, South Korea
- Oct 20, 2026Tango Therapeutics’ first study: phase 2 study in Lung NeoplasmsNew to Tango TherapeuticsTango Therapeutics · NCT07897734 · 188 planned
Ahead
- May 1, 2028Primary completion: phase 1 study in Neoplasm MetastasisErasca · NCT06983743
- Nov 2031Primary completion: phase 2 study in Lung NeoplasmsTango Therapeutics · NCT07897734
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07897734Lung Neoplasms | 2 | Not yet recruiting | Tango Therapeutics | Nov 2031 | 188 |
| NCT06983743Neoplasm Metastasis · United States, Canada, South Korea | 1 | Recruiting | Erasca | May 1, 2028 | 600 |
| NCT06895031Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Guangzhou JOYO Pharma | Mar 30, 2026 | 210 |
How it is read
Names in the registry
- “ERAS-0015”, 2 entries
- “ERAS-0015 in combination”, 1 entry
- “JYP0015”, 1 entry
Conditions, from the studies’ own filings
- Neoplasm Metastasis, 1 study
- Lung Neoplasms, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.